Fluorescent oxazoles from quinones for bioimaging applications

Gleiston G. Diasa, Pamella V. B. Pinhoa, Hélio A. Duartea, Jarbas M. Resendea, Andressa B. B. Rosab, José R. Correab, Brenno A. D. Neto*b and Eufrânio N. da Silva Júnior*a
aInstitute of Exact Sciences, Department of Chemistry, Federal University of Minas Gerais, Belo Horizonte, 31270-901, MG, Brazil. E-mail: eufranio@ufmg.br
bLaboratory of Medicinal & Technological Chemistry, Institute of Chemistry, University of Brasilia, P.O. Box 4478, Brasilia, 70904970, DF, Brazil. E-mail: brenno.ipi@gmail.com

Received 6th June 2016 , Accepted 1st August 2016

First published on 3rd August 2016


Abstract

This work describes a synthetic strategy for the syntheses of four new fluorescent excited state intramolecular proton transfer (ESIPT) prone oxazole derivatives synthesized from lapachol, a naturally occurring naphthoquinone isolated from the Tabebuia species (ipe tree). DFT calculations were performed to understand the ESIPT stabilizing process of these new derivatives. The new structures were designed to have improved lipophilic and balanced hydrophobic properties toward a selective cellular staining of lipid-based structures, that is, lipid inclusions in the cytosol. Cell-imaging experiments returned interesting results and showed the molecular architecture of the four derivatives had a great influence over the stabilizing processes in the excited state and over the selection of lipid inclusions inside the cells.


Introduction

The development of new, designed and more efficient bioprobes is a hard and challenging task.1 Whether one considers that the new probes must meet the strict requirements of chemical- and photostabilities associated with specific responses inside the astonishing cellular environment, than this task is even more puzzling.2–4 Most of the available cellular probes used for bioimaging applications, especially commercially available structures, have been built over a few ‘classical’ scaffolds i.e. coumarins, boron-dipyrromethenes (BODIPYs), rhodamines, cyanines, phenoxazines and fluoresceins. The great advances and drawbacks associated with these fluorescent derivatives have been reviewed elsewhere.5 Although derivatives synthesized from these scaffolds are commonly used for the development of bioprobes,6 many alternatives are emerging aiming to succeed where those derivatives have already shown their limitations and drawbacks, as some of us recently highlighted.7 Among the available alternatives, fluorescent derivatives bearing a unit of benzothiadiazole,8,9 benzothiazole,10,11 benzimidazole,12,13 imidazopyridine,14,15 and oxazole16,17 are some promising structures to further bioprobes technology.

Oxazole derivatives are a very attractive class of heterocycles prone to perform ESIPT (excited-state intramolecular proton transfer) stabilizing processes (Scheme 1).18–21 These derivatives may be used in many light technological areas and have been applied as fluorescent tags for multicomponent adducts,22 white emitters,23 probes for model membranes,24 metal sensors25 and others.26 Although oxazole derivatives are a promising class of fluorescent heterocycles, the rational design towards cellular selectivity in bioimaging experiments is a gap not fulfilled hitherto.


image file: c6ra14701a-s1.tif
Scheme 1 General structure of an ESIPT prone oxazole derivative and its excited-state intramolecular proton transfer mechanism. (i) Absorption, (ii) proton transfer in the excited state, (iii) emission and (iv) reverse proton transfer.

Because of our interest in the development new fluorescent probes for bioimaging applications,27–32 we disclose herein the syntheses of four new fluorescent oxazole derivatives, their molecular architecture designed for targeting lipophilic structures (lipids inclusions) inside the cells, their photophysical and theoretical (DFT) evaluations and their bioimaging applications.

Results and discussion

The new fluorescent derivatives were synthesized as shown in Scheme 2. The synthetic strategy was based on the redox center modification of β-lapachone and nor-β-lapachone derivatives prepared from the natural occurring lapachol (1), a quinone derivative easily obtained from ipe tree.33–36 We have successfully used this sort of strategy towards the synthesis of boron-based structures applied as superior probes for endocytic pathway tracking in live cancer cells30 and selective fluorescent sensor for cadmium ions.37 Lapachol (1) could be directed converted to nor-lapachol (2) by the well-established Hooker oxidation method38 and then transformed in the key intermediate 3-azide-nor-β-lapachone (3). Exploring the electrophilicity of the ortho-quinoidal carbonyls of the respective azide derivative by the reaction with salicylaldehyde in the presence of a nitrogen source the oxazole P1 was prepared.39 The click reaction40–42 of P1 afforded P2 bearing a long side carbon chain. Lapachol (1) was also used to obtain β-lapachone (2) which in turn was used to the synthesis of the iodinated oxazole (5). Key iodinated intermediate (5) directly afforded P3 and P4 through the Suzuki reaction.
image file: c6ra14701a-s2.tif
Scheme 2 Synthesis of fluorescent oxazole derivatives named P1–P4.

Derivative P1–P4 had their photophysical evaluated and results are summarized in Table 1 (also see Fig. S53–55 in the ESI file). P1 and P2 showed small Stokes shifts and reasonable molar extinction coefficients with log[thin space (1/6-em)]ε values in the range of 3.41–3.66 mM−1 cm−1. These data indicate the ESIPT were not as efficient as expected to be. P3 and P4 however showed a very distinct behavior. It could be noted (for P3 and P4) large Stokes shifts (141–184 nm) and large molar extinction coefficients (log[thin space (1/6-em)]ε values in the range of 4.08–4.39 mM−1 cm−1). ESIPT prone fluorophores typically have large Stokes shift and this feature is known to be a spectroscopic signature of the efficient process.43 Some theoretical calculations have been performed to a better understand of the photophysical related to the synthesized compounds, as show in Fig. 1.

Table 1 Photophysical data (in different solvents) for P1–P4 (10 μM solutions for all analyses)a
Oxazole Solvent λmax. (abs) (nm) log[thin space (1/6-em)]ε (ε) λmax. (em) (nm) Stokes shift (nm)
a Quantum yields (in dichloromethane) for P1–P4 of 0.70, 0.45, 0.55, and 0.51, respectively.
image file: c6ra14701a-u1.tif Ethyl acetate 370 3.57 (3736) 398 28
Acetonitrile 369 3.52 (3344) 400 31
Dichloromethane 372 3.57 (3708) 400 28
Dimethyl sulfoxide 374 3.57 (3708) 404 30
Hexane 369 3.66 (4530) 395 26
Methanol 369 3.56 (3671) 396 27
Toluene 374 3.59 (3868) 401 27
image file: c6ra14701a-u2.tif Ethyl acetate 369 3.51 (3225) 396 27
Acetonitrile 369 3.51 (3208) 397 28
Dichloromethane 371 3.54 (3482) 399 28
Dimethyl sulfoxide 373 3.41 (2574) 403 30
Hexane 368 3.64 (4365) 393 25
Methanol 368 3.52 (3305) 395 27
Toluene 372 3.58 (3781) 398 26
image file: c6ra14701a-u3.tif Ethyl acetate 378 4.28 (19[thin space (1/6-em)]068) 528 150
Acetonitrile 377 4.32 (21[thin space (1/6-em)]032) 525 148
Dichloromethane 380 4.31 (20[thin space (1/6-em)]432) 521 141
Dimethyl sulfoxide 381 4.32 (20[thin space (1/6-em)]736) 534 153
Hexane 378 4.39 (24[thin space (1/6-em)]436) 531 153
Methanol 377 4.22 (16[thin space (1/6-em)]652) 521 144
Toluene 383 4.33 (21[thin space (1/6-em)]606) 528 145
image file: c6ra14701a-u4.tif Ethyl acetate 363 4.30 (19[thin space (1/6-em)]726) 540 177
Acetonitrile 363 4.30 (19[thin space (1/6-em)]962) 541 178
Dichloromethane 365 4.33 (21[thin space (1/6-em)]572) 540 175
Dimethyl sulfoxide 367 4.26 (18[thin space (1/6-em)]276) 551 184
Hexane 360 4.34 (21[thin space (1/6-em)]740) 539 179
Methanol 363 4.08 (12[thin space (1/6-em)]090) 540 177
Toluene 366 4.26 (18[thin space (1/6-em)]284) 541 175



image file: c6ra14701a-f1.tif
Fig. 1 HOMO and LUMO plots and diagram of the frontier molecular orbital energies. Calculations performed at the PBEPBE/cc-pVDZ level of theory.

It is noted in both the ground and excited states the LUMO orbitals of P3 and P4 are centered in the oxazole ring whereas for P1 and P2 the same orbitals are more distributed in the structures. These results allow to a better understanding on the efficiency of the H-transfer in the excited state (ESIPT) for P3 and P4 and the large Stokes shifts obtained in the photophysical experiments.

Finally, compounds P1–P4 had their capacity as bioimaging probes tested against caco-2 (human colorectal adenocarcinoma cells) cells lineage (Fig. 2). All compounds could be visualized at the green channel bearing a strong fluorescence emission. Their lipophilic nature feature could be beneficially used in the experiments toward lipid inclusions staining.


image file: c6ra14701a-f2.tif
Fig. 2 (Left) Fixed caco-2 cell lineages stained with P1 and P2 (10 μM). (A) and (B) Fluorescence pattern of P1 and P2 (respectively) showing a disperse emission in the cytosol but with an accumulation near the peripheral regions of the cells (yellow arrow heads). These feature was more pronounced using P2 and the tendency toward lipid droplets (vesicles) could be clearer noted. (C) and (D) Show the normal morphological aspects of the samples by phase. (Right) Fixed caco-2 cell lineages stained with P3 and P4 (10 μM). (A) and (B) Fluorescence pattern of P3 and P4 (respectively) showing a disperse emission in the cytosol for P3 but with clear accumulation in the lipid inclusions for P4 (yellow arrow heads). (C) and (D) Show the normal morphological aspects of the samples by phase. N = nucleus and scale bar of 25 μM.

Compounds P1 and P2 displayed only the so-called minimum selection and were found in the cells' cytosol but not inside the nuclei. P1 was completely dispersed in the cytosol whereas compound P2 showed a tendency toward lipid droplets but it was also dispersed in the cytosol (leakage), therefore not suitable as a probe for analyzing these lipid inclusions. This tendency could be attributed to the long side carbon chain noted in P2 structure obtained from the azide in P1. In order to improve this tendency, we considered the substitution of the carbon chain for lipophilic and hydrophobic groups (e.g. aromatic groups) and, in this sense, compounds P3 and P4 were synthesized. P3 did not show the expected behavior and it was found mostly dispersed in the cytosol as P1. Only a tendency for lipids inclusions could be noted using P3. P4 showed however a better accumulation in the lipid bodies than the three previously tested compounds. Theoretical log[thin space (1/6-em)]P (clog[thin space (1/6-em)]P) values were calculated using DFT and semi-empirical levels (Table S6). The data corroborated the experimental observations and values of lipophilicity for P4 larger than those observed for P1–P3 were obtained. Commercial BODIPY was then used to compare and confirm the preference for lipid droplets of compound P4 and this feature could be therefore confirmed (Fig. 3 and S56).


image file: c6ra14701a-f3.tif
Fig. 3 Fixed caco-2 cell lineages stained with P4 (10 μM) and commercial available BODIPY. (A) Cells stained with P4 showing its accumulation in the lipid droplets (yellow arrowheads) and some part still dispersed in the cytosol. (B) Lipid droplets stained with BODIPY. (C) and (D) Show the normal morphological aspects of the samples by phase. N = nucleus and scale bar of 25 μM.

Fig. 3A shows the lipid droplets being gradually stained with P4. Even using the commercially available dye for lipid droplets (Fig. 3B), still some part of the dye was noted dispersed in the cytosol, especially considering fixed cells are being used. The selectivity noted for P4 may be attributed to its higher hydrophobic character indicating the rationale of its synthesis may be applied for further developments of new oxazole-based bioprobes. During the experiment time period no notable photobleaching or degradation could be observed for these dyes thus indicating the chemical- and photo-stabilities are sustained inside the cells, in accordance with the photostability experiment (Fig. S57). Commercial BODIPY is known to suffer from photobleaching and this feature limits long time period experiments. The obtained results for P4 are the first (to the best of our knowledge) toward a clear cellular selectivity of designed oxazoles from natural products therefore this work may be the bases for the development of other fluorescent oxazole derivatives from several classes of natural products, especially quinones.

Conclusions

For new fluorescent oxazole derivatives have been obtained from the natural product lapachol using an efficient synthetic methodology. Two of these derivatives (P3 and P4) prove to perform efficient ESIPT whereas the other two did not show the expected behavior in the excited state, although they proved to be stable emitters. DFT calculations allowed for a better understanding on the efficiency of the ESIPT processes of P3 and P4 and the LUMO orbitals were most centered in the oxazole ring. P1–P4 had their abilities as bioprobes tested against caco-2 cell lineages. P1 and P2 returned poor results whereas P3 showed a tendency to accumulate in lipid inclusions. P4 however proved to be the most selective fluorescent oxazole tested in this work and its molecular architecture may be used as the base for the development of new stable and selective emitters for bioimaging applications. Finally, it is important to add that although a huge progress is observed with these new designed oxazole derivatives, much is yet necessary to establish them as a new class of bioprobes and we are on the way to reach this goal.

Experimental section

General

Melting points were obtained on Thomas Hoover and are uncorrected. Analytical grade solvents were used. Column chromatography was performed on silica gel (SiliaFlash G60 UltraPure 60–200 μm, 60 Å). Infrared spectra were recorded on an FTIR Spectrometer IR Prestige-21 Shimadzu. 1H and 13C NMR spectra were recorded at 303 K using a Bruker AVANCE DRX400 spectrometer. All samples for NMR were prepared in CDCl3 containing TMS as internal reference. Chemical shifts (δ) are given in ppm and coupling constants (J) in hertz. High resolution mass spectra (electrospray ionization) were obtained using a MicroTOF Ic – Bruker Daltonics instrument.

Chemistry

Lapachol (1) was initially extracted from the heartwood of Tabebuia sp. (Tecoma) and purified by a series of recrystallizations. Initially, nor-lapachol (2) was synthesized by Hooker oxidation methodology38 and data are consistent with those reported in the literature.44–46 Compound 2 was obtained as an orange solid (160 mg, 0.7 mmol, 70% yield); mp 121–122 °C.38 1H NMR (400 MHz, CDCl3, 303 K) δ: 8.13 (ddd, 1H, J = 7.5, 1.5 and 0.5 Hz), 8.10 (ddd, 1H, J = 7.5, 1.5 and 0.5 Hz), 7.76 (td, 1H, J = 7.5, 7.5 and 1.5 Hz), 7.69 (td, 1H, J = 7.5, 7.5 and 1.5 Hz), 6.03–5.99 (m, 1H), 2.0 (d, 3H, J = 1.5 Hz), 1.68 (d, 3H, J = 1.2 Hz). 13C NMR (100 MHz, CDCl3, 303 K) δ: 184.7, 181.5, 151.1, 143.6, 134.9, 133.0, 132.9, 129.5, 126.9, 126.0, 120.9, 113.6, 26.5, 21.7.
Synthesis of 3-azido-2,2-dimethyl-2,3-dihydronaphtho[1,2-b]furan-4,5-dione (3). To a solution of nor-lapachol (2) (228 mg, 1.0 mmol) in 25 mL of dichloromethane, 2 mL of bromine was added. The bromo intermediate precipitated immediately as an orange solid. After removal of bromine, by adding dichloromethane and then removing the organic solvent with dissolved bromine by rotary evaporator, an excess of sodium azide (2 mmol) was added in CH2Cl2 and the mixture was stirred overnight. The crude reaction mixture was poured into 50 mL of water. The organic phase was extracted with organic solvent, dried over sodium sulfate, filtered, and evaporated under reduced pressure. The product 3 was obtained after recrystallization as an orange solid (263 mg, 0.98 mmol, 98% yield); mp 200–202 °C. 1H NMR (400 MHz, CDCl3, 303 K) δ: 8.14 (ddd, 1H, J = 6.9, 2.1 and 0.9 Hz), 7.72–7.65 (3H, m), 4.77 (1H, s), 1.67 (3H, s), 1.55 (3H, s). 13C NMR (100 MHz, CDCl3, 303 K) δ: 180.3, 175.2, 170.2, 134.5, 132.7, 131.1, 113.5, 129.5, 125.1, 126.7, 95.5, 67.3, 27.1, 21.9. Data are consistent with those reported in the literature.47
General procedure for the synthesis of β-lapachone (4). Sulfuric acid was slowly added to lapachol (1) (1 mmol, 242 mg) until complete dissolution of the quinone. Then, the solution was poured into ice and the precipitate formed was filtered and washed with water. β-Lapachone (4) was recrystallized in an appropriate solvent, as for instance, ethanol. Compound 4 was obtained as an orange solid (240 mg, 99% yield); mp 153–155 °C. 1H NMR (400 MHz, CDCl3, 303 K) δ: 8.06 (dd, 1H, J = 7.6 and 1.4 Hz), 7.81 (dd, 1H, J = 7.8 and 1.1 Hz), 7.65 (ddd, 1H, J = 7.8, 7.6 and 1.4 Hz), 7.51 (td, 1H, J = 7.6, 7.6 and 1.1 Hz), 2.57 (t, 2H, J = 6.7 Hz), 1.86 (t, 2H, J = 6.7 Hz), 1.47 (s, 6H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 179.8, 178.5, 162.0, 134.7, 132.6, 130.6, 130.1, 128.5, 124.0, 112.7, 79.3, 31.6, 26.8, 16.2. Data are consistent with those reported in the literature.48,49
General procedure for the syntheses of P1 and the iodinated derivative 5 (oxazole formation)39,50. To a solution of 3-azide-nor-β-lapachone (3) (1.0 mmol) or β-lapachone (4) (242 mg, 1 mmol) in acetic acid (10 mL), salicylaldehyde (244 mg, 0.2 mL, 2.0 mmol) or 2-hydroxy-3,5-diiodobenzaldehyde (561 mg, 1.5 mmol) was added, and the mixture was heated to 70 °C; at this point, ammonium acetate (1.54 g, 20 mmol) was slowly added, and the temperature was maintained at 110 °C. All the reactions were monitored by thin layer chromatography and it was observed that after four hours all the starting material was consumed. At this point, the reaction was cooled to room temperature and extracted with dichloromethane and dried with Na2SO4. The solvent was removed under reduced pressure to afford the crude product, which was purified on a silica column using a gradient mixture of hexane/ethyl acetate as eluent (1% of ethyl acetate in hexane).

Compound P1 was obtained as a white solid (196 mg, 0.7 mmol, 72% yield); mp 169–170 °C. 1H NMR (400 MHz, CDCl3, 303 K) δ: 1.58 (s, 3H), 1.73 (s, 3H), 5.13 (s, 1H), 7.03 (ddd, 1H, J = 7.9, 7.3 and 1.1 Hz), 7.15 (ddd, 1H, J = 8.3, 1.1 and 0.4 Hz), 7.42 (ddd, 1H, J = 8.3, 7.3 and 1.7 Hz), 8.06 (ddd, 1H, J = 7.9, 1.7 and 0.4 Hz), 7.55 (ddd, 1H, J = 8.3, 7.0 and 1.2 Hz), 7.71 (ddd, 1H, J = 8.3, 7.0 and 1.2 Hz), 8.11 (ddd, 1H, J = 8.3, 1.2 and 0.8 Hz), 8.44 (ddd, 1H, J = 8.3, 1.2 and 0.8 Hz), 11.38 (s, 1H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 22.3, 27.4, 69.4, 91.4, 102.7, 111.1, 117.3, 119.1, 119.7, 122.5, 123.4, 125.4, 126.5, 126.6, 128.6, 130.1, 132.7, 143.2, 155.5, 157.7, 160.6. EI/HRMS (m/z) [M + H]+: 373.1285. Cald for [C21H17N4O3]+: 373.1300.

Compound 5 was obtained as a grey solid (378 mg, 0.76 mmol, 76% yield); mp 279–280 °C. 1H NMR (400 MHz, CDCl3, 303 K) δ: 1.43 (s, 6H), 1.95 (t, 2H, J = 6.6 Hz), 3.06 (t, 2H, J = 6.6 Hz), 7.43–7.49 (m, 1H), 7.53–7.60 (m, 1H), 8.05 (d, 1H, J = 2.1 Hz), 8.20 (d, 1H, J = 2.1 Hz), 8.21–8.26 (m, 2H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 17.4, 26.7, 31.6, 75.7, 81.0, 86.5, 101.6, 113.2, 121.6, 122.9, 124.3, 125.2, 127.2, 127.4, 134.4, 139.1, 146.9, 148.4, 149.0, 156.2, 157.7.

Click chemistry reaction for preparing P2 was accomplished as previously classical procedure described by Sharpless with minor modifications.40 Compound P1 (136 mg, 0.5 mmol) was reacted with CuSO4·5H2O (0.04 mmol), sodium ascorbate (0.15 mmol) and 1-pentadecyne (217 mg, 0.28 mL, 1.0 mmol) in a mixture of CH2Cl2[thin space (1/6-em)]:[thin space (1/6-em)]H2O (15 mL, 2[thin space (1/6-em)]:[thin space (1/6-em)]1, v/v). The mixture was stirred at room temperature, and, the reaction was monitored by thin layer chromatography. The aqueous phase was extracted with CH2Cl2, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with a gradient mixture of hexane[thin space (1/6-em)]:[thin space (1/6-em)]ethyl acetate. With 1% of ethyl acetate in hexane the product was eluted and isolated as a white solid. Compound P2 was obtained as a white solid (162 mg, 0.38 mmol, 75% yield); mp 143–144 °C. 1H NMR (400 MHz, CDCl3, 303 K) δ: 0.87 (t, 3H J = 7.0 Hz), 1.10–1.33 (m, 23H), 1.55 (q, 2H, J = 7.4 Hz), 1.76 (s, 3H), 2.53–2.68 (m, 2H), 6.47 (s, 1H), 6.81 (s, 1H), 6.96 (ddd, 1H, J = 7.9, 1.7 and 0.4 Hz), 7.11 (ddd, 1H, J = 8.3, 1.1 and 0.4 Hz), 7.39 (ddd, 1H, J = 8.3, 7.2 and 1.7 Hz), 7.62 (ddd, 1H, J = 8.3, 7.0 and 1.2 Hz), 7.78 (ddd, 1H, J = 8.3, 7.0 and 1.2 Hz), 7.87 (ddd, 1H, J = 7.9, 1.7 and 0.4 Hz), 8.19 (ddd, 1H, J = 8.3, 1.2 and 0.8 Hz), 8.48 (ddd, 1H, J = 8.3, 1.2 and 0.8 Hz), 11.31 (s, 1H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 14.1, 21.7, 22.7, 25.7, 27.3, 29.1, 29.2, 29.3, 29.4(6), 29.5(5), 29.5(8), 29.6(1), 29.6(4), 31.9, 68.1, 91.9, 117.2, 101.3, 110.7, 119.1, 119.7, 119.9, 122.6, 123.5, 125.8, 126.6, 126.9, 129.1, 130.6, 132.9, 142.6, 148.8, 156.1, 157.7, 160.9. Two 13C resonances were observed at 29.2, as confirmed by HSQC analysis. Some of the 13C chemical shifts were indicated with two decimals in order to differentiate nuclei with very similar resonance frequencies. EI/HRMS (m/z) [M + H]+: 581.3501. Cald for [C36H45N4O3]+: 581.3491.

General procedure for the syntheses of P3 and P4 (Suzuki reaction). In a Schlenk tube was added iodinated oxazole 5 (239 mg, 0.4 mmol), phenylboronic acid (1.0 mmol), palladium(II) acetate (3 mg, 0.01 mmol), triphenylphosphine (11 mg, 0.04 mmol) sodium carbonate (350 mg, 3.2 mmol), 2 mL of water, 1 mL of methanol and 12 mL of toluene. The Schlenk tube was sealed and heated to 70 °C for 36 hours. The reaction was cooled to room temperature and the solvent was evaporated under reduced pressure. The product was extracted with dichloromethane and dried with Na2SO4. The solvent was removed under reduced pressure to afford the crude product, which was purified on a silica column using a gradient mixture of hexane/ethyl acetate as eluent (1% of ethyl acetate in hexane).

Compound P3 was obtained as a yellow solid (160 mg, 0.30 mmol, 80% yield); mp 247–248 °C. 1H NMR (400 MHz, CDCl3, 303 K) δ: 1.49 (s, 6H), 2.01 (t, 2H, J = 6.6 Hz), 3.14 (t, 2H, J = 6.6 Hz), 7.44–7.53 (m, 5H), 7.60 (ddd, 1H, J = 8.3, 6.9 and 1.2 Hz), 7.66–7.69 (m, 2H), 7.72–7.76 (m, 2H), 8.23 (d, 1H, J = 2.4 Hz), 8.30 (dd, 2H, J = 8.3 and 1.1 Hz), 12.20 (s, 1H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 17.5, 26.8, 31.7, 75.5, 101.7, 112.1, 121.6, 122.8, 123.8, 124.2, 124.4, 124.9, 126.9, 127.1, 127.4, 127.5, 128.2, 128.9, 129.5, 130.6, 132.1, 132.7, 137.9, 140.4, 146.5, 148.4, 154.4, 160.4. Two 13C resonances were observed at 127.1, as confirmed by HSQC analysis. EI/HRMS (m/z) [M + H]+: 498.2063. Cald for [C34H28NO3]+: 498.2069.

Compound P4 was obtained as a yellow solid (100 mg, 0.18 mmol, 61% yield); mp 227–228 °C. 1H NMR (400 MHz, CDCl3, 303 K) δ: 1.48 (s, 6H), 2.00 (t, 2H, J = 6.4 Hz), 3.13 (t, 2H, J = 6.4 Hz), 3.85 (s, 3H), 3.87 (s, 3H), 6.99 (d, 1H, J = 8.7 Hz), 7.03 (d, 1H, J = 8.4 Hz), 7.44–7.52 (m, 1H), 7.55–7.63 (m, 4H), 7.67 (d, 2H, J = 8.4 Hz), 8.12 (d, 1H, J = 1.8 Hz), 8.28 (d, 1H, J = 8.6 Hz), 12.11 (s, 1H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 17.5, 26.8, 31.7, 55.4, 75.5, 101.7, 111.9, 113.7, 114.3, 121.6, 122.8, 122.9, 124.1, 124.4, 124.8, 127.0, 127.5, 127.9, 130.1, 130.3, 130.6, 131.6, 132.4, 133.1, 146.4, 148.3, 159.0, 159.1, 153.9, 160.6. EI/HRMS (m/z) [M + H]+: 558.2285 cald for [C36H32NO5]+: 558.2280.

Acknowledgements

This research was funded by grants from CNPq (PVE 401193/2014-4), FAPEMIG (Edital 01/2014 (APQ-02478-14) and Programa Pesquisador Mineiro – PPM X), CAPES, FAPDF, FINATEC, DPP-UnB, INCT-Transcend group and CAPES/PROCAD.

References

  1. A. Nadler and C. Schultz, Angew. Chem., Int. Ed., 2013, 52, 2408–2410 CrossRef CAS PubMed.
  2. K. Kikuchi, Chem. Soc. Rev., 2010, 39, 2048–2053 RSC.
  3. J. Liang, B. Z. Tang and B. Liu, Chem. Soc. Rev., 2015, 44, 2798–2811 RSC.
  4. D. Ding, K. Li, B. Liu and B. Z. Tang, Acc. Chem. Res., 2013, 46, 2441–2453 CrossRef CAS PubMed.
  5. L. D. Lavis and R. T. Raines, ACS Chem. Biol., 2014, 9, 855–866 CrossRef CAS PubMed.
  6. S. H. Alamudi, R. Satapathy, J. Kim, D. Su, H. Ren, R. Das, L. Hu, E. Alvarado-Martinez, J. Y. Lee, C. Hoppmann, E. Pena-Cabrera, H.-H. Ha, H.-S. Park, L. Wang and Y.-T. Chang, Nat. Commun., 2016, 7, 11964 CrossRef CAS PubMed.
  7. B. A. D. Neto, P. H. P. R. Carvalho and J. R. Correa, Acc. Chem. Res., 2015, 48, 1560–1569 CrossRef CAS PubMed.
  8. B. A. D. Neto, A. A. M. Lapis, E. N. da Silva Júnior and J. Dupont, Eur. J. Org. Chem., 2013, 228–255 CrossRef CAS.
  9. B. A. D. Neto, J. R. Correa and R. G. Silva, RSC Adv., 2013, 3, 5291–5301 RSC.
  10. Y. Kim, M. Choi, S. Seo, S. T. Manjare, S. Jon and D. G. Churchill, RSC Adv., 2014, 4, 64183–64186 RSC.
  11. S. Goswami, S. Das, K. Aich, B. Pakhira, S. Panja, S. K. Mukherjee and S. Sarkart, Org. Lett., 2013, 15, 5412–5415 CrossRef CAS PubMed.
  12. A. K. Mahapatra, K. Maiti, S. K. Manna, R. Maji, C. Das Mukhopadhyay, B. Pakhira and S. Sarkar, Chem.–Asian J., 2014, 9, 3623–3632 CrossRef CAS PubMed.
  13. A. Paul, S. Anbu, G. Sharma, M. L. Kuznetsov, M. da Silva, B. Koch and A. J. L. Pombeiro, Dalton Trans., 2015, 44, 16953–16964 RSC.
  14. M. Roy, B. Chakravarthi, C. Jayabaskaran, A. A. Karande and A. R. Chakravarty, Dalton Trans., 2011, 40, 4855–4864 RSC.
  15. S. T. Nguyen, S. M. Kwasny, X. Y. Ding, J. D. Williams, N. P. Peet, T. L. Bowlin and T. J. Opperman, Bioorg. Med. Chem., 2015, 23, 5789–5798 CrossRef CAS PubMed.
  16. Y. C. Hao, M. L. Zheng and Y. Chen, J. Mater. Chem. B, 2014, 2, 7369–7374 RSC.
  17. Q. Wang, L. Zhou, L. Qiu, D. Lu, Y. Wu and X.-B. Zhang, Analyst, 2015, 140, 5563–5569 RSC.
  18. C. Li, Y. Yang, C. Ma and Y. Liu, RSC Adv., 2016, 6, 5134–5140 RSC.
  19. Y. Xu, L. Xiao, S. Sun, Z. Pei, Y. Pei and Y. Pang, Chem. Commun., 2014, 50, 7514–7516 RSC.
  20. Y. Houari, A. Charaf-Eddin, A. D. Laurent, J. Massue, R. Ziessel, G. Ulrich and D. Jacquemin, Phys. Chem. Chem. Phys., 2014, 16, 1319–1321 RSC.
  21. J. Massue, G. Ulrich and R. Ziessel, Eur. J. Org. Chem., 2013, 2013, 5701–5709 CrossRef CAS.
  22. R. F. Affeldt, R. S. Iglesias, F. S. Rodembusch and D. Russowsky, J. Phys. Org. Chem., 2012, 25, 769–777 CrossRef CAS.
  23. K. Benelhadj, W. Muzuzu, J. Massue, P. Retailleau, A. Charaf-Eddin, A. D. Laurent, D. Jacquemin, G. Ulrich and R. Ziessel, Chem.–Eur. J., 2014, 20, 12843–12857 CrossRef CAS PubMed.
  24. P. F. Dick, F. L. Coelho, F. S. Rodembusch and L. F. Campo, Tetrahedron Lett., 2014, 55, 3024–3029 CrossRef.
  25. J. E. Kwon, S. Lee, Y. You, K. H. Baek, K. Ohkubo, J. Cho, S. Fukuzumi, I. Shin, S. Y. Park and W. Nam, Inorg. Chem., 2012, 51, 8760–8774 CrossRef CAS PubMed.
  26. V. S. Patil, V. S. Padalkar, A. B. Tathe, V. D. Gupta and N. Sekar, J. Fluoresc., 2013, 23, 1019–1029 CrossRef CAS PubMed.
  27. S. T. A. Passos, J. R. Correa, S. L. M. Soares, W. A. da Silva and B. A. D. Neto, J. Org. Chem., 2016, 81, 2646–2651 CrossRef CAS PubMed.
  28. A. A. R. Mota, J. R. Corrêa, P. H. P. R. Carvalho, N. M. P. de Sousa, H. C. B. de Oliveira, C. C. Gatto, D. A. da Silva Filho, A. L. de Oliveira and B. A. D. Neto, J. Org. Chem., 2016, 81, 2958–2965 CrossRef CAS PubMed.
  29. C. D'Angelis do, E. S. Barbosa, J. R. Corrêa, G. A. Medeiros, G. Barreto, K. G. Magalhães, A. L. de Oliveira, J. Spencer, M. O. Rodrigues and B. A. D. Neto, Chem.–Eur. J., 2015, 21, 5055–5060 CrossRef PubMed.
  30. G. G. Dias, B. L. Rodrigues, J. M. Resende, H. D. R. Calado, C. A. de Simone, V. H. C. Silva, B. A. D. Neto, M. O. F. Goulart, F. R. Ferreira, A. S. Meira, C. Pessoa, J. R. Correa and E. N. da Silva Júnior, Chem. Commun., 2015, 51, 9141–9144 RSC.
  31. P. H. P. R. Carvalho, J. R. Correa, B. C. Guido, C. C. Gatto, H. C. B. De Oliveira, T. A. Soares and B. A. D. Neto, Chem.–Eur. J., 2014, 20, 15360–15374 CrossRef CAS PubMed.
  32. J. R. Diniz, J. R. Correa, D. D. Moreira, R. S. Fontenele, A. L. de Oliveira, P. V. Abdelnur, J. D. L. Dutra, R. O. Freire, M. O. Rodrigues and B. A. D. Neto, Inorg. Chem., 2013, 52, 10199–10205 CrossRef CAS PubMed.
  33. S. L. de Castro, F. S. Emery and E. N. da Silva Júnior, Eur. J. Med. Chem., 2013, 69, 678–700 CrossRef CAS PubMed.
  34. E. N. da Silva Júnior, G. A. M. Jardim, R. F. S. Menna-Barreto and S. L. de Castro, J. Braz. Chem. Soc., 2014, 25, 1780–1798 Search PubMed.
  35. G. A. M. Jardim, W. J. Reis, M. F. Ribeiro, F. M. Ottoni, R. J. Alves, T. L. Silva, M. O. F. Goulart, A. L. Braga, R. F. S. Menna-Barreto, K. Salomao, S. L. de Castroe and E. N. da Silva Júnior, RSC Adv., 2015, 5, 78047–78060 RSC.
  36. E. H. G. da Cruz, M. A. Silvers, G. A. M. Jardim, J. M. Resende, B. C. Cavalcanti, I. S. Bomfim, C. Pessoa, C. A. de Simone, G. V. Botteselle, A. L. Braga, D. K. Nair, I. N. N. Namboothiri, D. A. Boothman and E. N. da Silva Júnior, Eur. J. Med. Chem., 2016, 122, 1–16 CrossRef CAS PubMed.
  37. G. A. M. Jardim, H. D. R. Calado, L. A. Cury and E. N. da Silva Júnior, Eur. J. Org. Chem., 2015, 703–709 CrossRef CAS.
  38. L. F. Fieser and M. Fieser, J. Am. Chem. Soc., 1948, 70, 3215–3222 CrossRef CAS PubMed.
  39. C. N. Pinto, A. P. Dantas, K. C. G. De Moura, F. S. Emery, P. F. Polequevitch, M. D. Pinto, S. L. de Castro and A. V. Pinto, Arzneimittelforschung, 2000, 50, 1120–1128 CAS.
  40. H. C. Kolb, M. G. Finn and K. B. Sharpless, Angew. Chem., Int. Ed., 2001, 40, 2004–2021 CrossRef CAS.
  41. C. W. Tornoe, C. Christensen and M. Meldal, J. Org. Chem., 2002, 67, 3057–3064 CrossRef CAS PubMed.
  42. M. Meldal and C. W. Tornoe, Chem. Rev., 2008, 108, 2952–3015 CrossRef CAS PubMed.
  43. B. K. Paul, A. Samanta and N. Guchhait, J. Fluoresc., 2011, 21, 1265–1279 CrossRef CAS PubMed.
  44. D. R. da Rocha, K. Mota, I. M. C. B. da Silva, V. F. Ferreira, S. B. Ferreira and F. C. da Silva, Tetrahedron, 2014, 70, 3266–3270 CrossRef CAS.
  45. M. Niehues, V. P. Barros, F. S. Emery, M. Dias-Baruffi, M. d. D. Assis and N. P. Lopes, Eur. J. Med. Chem., 2012, 54, 804–812 CrossRef CAS PubMed.
  46. E. P. Sacau, A. Estevez-Braun, A. G. Ravelo, E. A. Ferro, H. Tokuda, T. Mukainaka and H. Nishino, Bioorg. Med. Chem., 2003, 11, 483–488 CrossRef CAS PubMed.
  47. E. N. da Silva Júnior, R. F. S. Menna-Barreto, M. Pinto, R. S. F. Silva, D. V. Teixeira, M. de Souza, C. A. De Simone, S. L. De Castro, V. F. Ferreira and A. V. Pinto, Eur. J. Med. Chem., 2008, 43, 1774–1780 CrossRef PubMed.
  48. S. C. Hooker, J. Am. Chem. Soc., 1936, 58, 1190–1197 CrossRef CAS.
  49. K. Schaffnersabba, K. H. Schmidtruppin, W. Wehrli, A. R. Schuerch and J. W. F. Wasley, J. Med. Chem., 1984, 27, 990–994 CrossRef CAS.
  50. K. C. G. De Moura, F. S. Emery, C. Neves-Pinto, M. Pinto, A. P. Dantas, K. Salomao, S. L. de Castro and A. V. Pinto, J. Braz. Chem. Soc., 2001, 12, 325–338 CrossRef CAS.

Footnote

Electronic supplementary information (ESI) available: 1D and 2D NMR spectra, HRMS [ESI(+)-MS], photophysical analyses, cellular experimental procedures and Cartesian coordinates for the calculated structures, and energy and thermal corrections. See DOI: 10.1039/c6ra14701a

This journal is © The Royal Society of Chemistry 2016
Click here to see how this site uses Cookies. View our privacy policy here.